Chikanishi Miyako M, Tanuma Junko, Ishii Kenji, Sakata Muneyuki, Arai Noritoshi, Noguchi Tomoyuki, Komatsu Kensuke, Ito Kimiteru, Mizoue Tetsuya, Kubota Kazuo, Watadani Takeyuki, Gatanaga Hiroyuki, Oka Shinichi
Department of Neuroradiology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan.
Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan.
Glob Health Med. 2024 Dec 31;6(6):420-426. doi: 10.35772/ghm.2024.01039.
Patient-specific brain fluorodeoxyglucose-positron emission tomography (FDG PET) can detect areas with abnormal FDG uptake in patients with human immunodeficiency virus (HIV) before and after combination antiretroviral therapy (cART). There were few reports about the same patients before and shortly after cART in FDG PET. It is well known that HIV-RNA levels decrease and cognitive impairments in patients with HIV tend to improve on neurocognitive performance tests 6 months after starting cART. We conducted a quantitative imaging analysis (FDG PET and voxel-based morphometry (VBM)) of eight patients at pre- and 6 months post- cART with neurocognitive performance tests. In terms of participant-specific changes between pre- and post-cART imaging, some area showed that the size of area with abnormal FDG uptake shrunk and became a nearly physiological level at 6 months post-cART. No apparent changes in VBM were observed in this short period. FDG PET might detect the first effect of cART.
针对个体患者的脑氟脱氧葡萄糖正电子发射断层扫描（FDG PET）能够在接受联合抗逆转录病毒治疗（cART）前后，检测出人类免疫缺陷病毒（HIV）患者中FDG摄取异常的区域。关于同一组患者在cART治疗前及治疗后不久进行FDG PET检查的报道较少。众所周知，HIV-RNA水平会下降，并且HIV患者的认知障碍在开始cART治疗6个月后的神经认知功能测试中往往会有所改善。我们对8名患者在cART治疗前和治疗后6个月进行了定量成像分析（FDG PET和基于体素的形态测量法（VBM））以及神经认知功能测试。就cART治疗前后成像的个体特异性变化而言，一些区域显示，FDG摄取异常区域的大小在cART治疗后6个月时缩小并接近生理水平。在这一短时间内未观察到VBM有明显变化。FDG PET可能检测到cART的首个效果。
